SLC2A1 and acute myeloid leukemia: In this regard, our successful exploration of GLUT1-overexpressed Jurkat (non-specific T cells) in this study suggests the potential feasibility of utilizing alternative non-specific cell vehicles against leukemic blasts like healthy hematopoietic stem cells (HSCs), or HSCs-derived engineered natural killer T cells [86] (NK-T cells) and empowering them with GLUT1-overexpressed gene therapy in adoptive cell transfer to treat AML.